Olivia D Jee, MD
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jee’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A130448 · Current
Licensed to practise in California · since 2014 · expires 2028-01-31 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$13,072
Medicare paid this office $13,072 for 104 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 36 | $3,616 | $56 |
| Long return visit (40+ min) | 26 | $3,043 | $59 |
| Short return visit (20+ min) | 41 | $2,708 | $51 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 34 | $2,211 | $65 |
| Short return visit | 15 | $817 | $48 |
Who their Medicare patients are
104 Original Medicare patients in 2024. Average age 72 · Women 64% · Also on Medicaid 12% · Health risk score 1.06. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 50% · Diabetes 31% · Coronary heart disease 22% · Chronic kidney disease 17% · Cancer 15% · Depression 15% · Atrial fibrillation 11%.
The office billed $114,947, Medicare allowed $19,850 and paid $13,072; for 230 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 104 | 230 | 72 | 1.06 | $114,947 | $13,072 |
| 2023 | 82 | 190 | 72 | 1.18 | $94,709 | $12,465 |
| 2022 | 80 | 151 | 73 | 0.94 | $72,238 | $10,291 |
| 2021 | 37 | 62 | 71 | 1.05 | $26,420 | $3,753 |
| 2020 | 57 | 122 | 72 | 1.14 | $42,374 | $8,337 |
| 2019 | 41 | 55 | 69 | 0.96 | $10,277 | $4,150 |
| 2018 | 58 | 111 | 71 | 1.10 | $17,492 | $7,950 |
| 2017 | 58 | 118 | 68 | 1.41 | $26,020 | $9,411 |
| 2016 | 81 | 153 | 67 | 1.32 | $42,074 | $12,419 |
| 2015 | 24 | 31 | 70 | 1.45 | $10,922 | $2,843 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 32 | $6,080 | $81 |
| Return visit (30+ min) | 40 | $2,886 | $57 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 22 | $1,388 | $63 |
| Short return visit (20+ min) | 21 | $1,278 | $51 |
2022: 4 services
| Long return visit (40+ min) | 24 | $2,985 | $79 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 30 | $1,963 | $65 |
| Return visit (30+ min) | 21 | $1,443 | $56 |
| Short return visit (20+ min) | 22 | $1,344 | $48 |
2021: 1 service
| Short return visit (20+ min) | 14 | $803 | $47 |
2020: 3 services
| Return visit (30+ min) | 21 | $2,168 | $75 |
| Short return visit (20+ min) | 26 | $1,680 | $43 |
| Long return visit (40+ min) | 11 | $1,310 | $101 |
2019: 2 services
| Return visit (30+ min) | 19 | $1,689 | $70 |
| Short return visit (20+ min) | 16 | $696 | $44 |
2018: 3 services
| Return visit (30+ min) | 34 | $3,445 | $60 |
| Long return visit (40+ min) | 14 | $2,371 | $95 |
| Short return visit (20+ min) | 11 | $443 | $40 |
2017: 2 services
| Return visit (30+ min) | 34 | $3,438 | $60 |
| Long return visit (40+ min) | 17 | $3,288 | $94 |
2016: 4 services
| Long return visit (40+ min) | 25 | $3,406 | $97 |
| Return visit (30+ min) | 36 | $2,947 | $59 |
| New patient visit (45+ min) | 12 | $976 | $81 |
| Short return visit (20+ min) | 22 | $916 | $40 |
Drugs they prescribed that Part D paid
$65,191
Pharmacies billed $65,191 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
607 generic and fewer than 11 brand-name prescriptions · $65,191 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 28 | $15,585 | $557 |
| Myrbetriq | 14 | $5,823 | $416 |
| Gabapentin | 19 | $478 | $25 |
| Bupropion Xl | 13 | $389 | $30 |
| Atorvastatin | 44 | $347 | $8 |
See all 18 drugs
| Jardiance | 28 | $15,585 | $557 |
| Myrbetriq | 14 | $5,823 | $416 |
| Gabapentin | 19 | $478 | $25 |
| Bupropion Xl | 13 | $389 | $30 |
| Atorvastatin | 44 | $347 | $8 |
| Levothyroxine | 24 | $334 | $14 |
| Tamsulosin | 14 | $313 | $22 |
| Omeprazole | 21 | $280 | $13 |
| Metformin Hcl Er | 26 | $238 | $9 |
| Losartan | 29 | $200 | $7 |
| Amlodipine Besylate | 21 | $194 | $9 |
| Rosuvastatin | 15 | $182 | $12 |
| Zolpidem | 15 | $93 | $6 |
| Simvastatin | 12 | $64 | $5 |
| Doxazosin Mesylate | 14 | $49 | $4 |
| Clonazepam | 13 | $47 | $4 |
| Chlorhexidine Gluconate | 13 | $45 | $3 |
| Famotidine | 14 | $43 | $3 |
Year by year
| 2024 | 700 | 87 | None | None | $65,191 |
| 2023 | 693 | 88 | None | None | $89,683 |
| 2022 | 529 | 85 | 0% (0) | None | $59,344 |
| 2021 | 502 | 65 | 0% (0) | None | $44,758 |
| 2020 | 675 | 87 | None | None | $59,418 |
| 2019 | 457 | 65 | 0% (0) | None | $36,248 |
| 2018 | 803 | 93 | 0% (0) | 19% | $77,842 |
| 2017 | 863 | 110 | 3% (23) | 14% | $97,336 |
| 2016 | 512 | 73 | 3% (13) | None | $50,915 |
| 2015 | 295 | 45 | 5% (14) | None | $15,668 |
| 2014 | 199 | 41 | 7% (14) | None | $13,824 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Trulicity | 23 | $22,630 | $984 |
| Rosuvastatin | 14 | $917 | $65 |
| Gabapentin | 20 | $531 | $27 |
| Fluticasone Propionate | 16 | $520 | $32 |
| Levothyroxine | 33 | $447 | $14 |
| Losartan | 35 | $430 | $12 |
| Metformin Hcl Er | 35 | $369 | $11 |
| Atorvastatin | 34 | $348 | $10 |
| Famotidine | 15 | $343 | $23 |
| Doxazosin Mesylate | 12 | $311 | $26 |
| Amlodipine Besylate | 28 | $299 | $11 |
| Omeprazole | 29 | $299 | $10 |
| Lamotrigine | 15 | $171 | $11 |
| Irbesartan-Hydrochlorothiazide | 12 | $163 | $14 |
| Fluoxetine | 12 | $152 | $13 |
| Fosinopril | 11 | $140 | $13 |
| Sertraline | 13 | $129 | $10 |
| Metformin | 15 | $122 | $8 |
| Zolpidem | 18 | $82 | $5 |
2022: 16 drugs
| Trulicity | 18 | $19,667 | $1,093 |
| Movantik | 12 | $4,985 | $415 |
| Olopatadine | 15 | $2,138 | $143 |
| Levothyroxine | 26 | $418 | $16 |
| Atorvastatin | 32 | $358 | $11 |
| Losartan | 25 | $347 | $14 |
| Omeprazole | 28 | $345 | $12 |
| Amlodipine Besylate | 22 | $280 | $13 |
| Famotidine | 12 | $234 | $20 |
| Gabapentin | 14 | $211 | $15 |
| Lisinopril | 14 | $140 | $10 |
| Pantoprazole | 13 | $135 | $10 |
| Metformin | 16 | $121 | $8 |
| Lamotrigine | 13 | $103 | $8 |
| Sertraline | 17 | $89 | $5 |
| Metformin Hcl Er | 14 | $75 | $5 |
2021: 18 drugs
| Myrbetriq | 16 | $7,058 | $441 |
| Olopatadine | 16 | $1,786 | $112 |
| Losartan | 27 | $731 | $27 |
| Levothyroxine | 27 | $424 | $16 |
| Atorvastatin | 28 | $409 | $15 |
| Fluticasone Propionate | 24 | $394 | $16 |
| Fosinopril | 11 | $292 | $27 |
| Gabapentin | 11 | $281 | $26 |
| Omeprazole | 26 | $265 | $10 |
| Amlodipine Besylate | 19 | $192 | $10 |
| Lamotrigine | 14 | $181 | $13 |
| Lisinopril | 18 | $169 | $9 |
| Famotidine | 14 | $168 | $12 |
| Pantoprazole | 18 | $166 | $9 |
| Metformin | 12 | $149 | $12 |
| Fluoxetine | 13 | $137 | $11 |
| Irbesartan-Hydrochlorothiazide | 11 | $114 | $10 |
| Sertraline | 12 | $61 | $5 |
2020: 23 drugs
| Linzess | 20 | $11,979 | $599 |
| Myrbetriq | 16 | $6,712 | $419 |
| Levothyroxine | 37 | $758 | $20 |
| Gabapentin | 22 | $568 | $26 |
| Atorvastatin | 35 | $501 | $14 |
| Tamsulosin | 13 | $462 | $36 |
| Losartan | 20 | $435 | $22 |
| Olopatadine | 17 | $429 | $25 |
| Fluticasone Propionate | 16 | $227 | $14 |
| Lisinopril | 32 | $208 | $6 |
| Metformin Hcl Er | 22 | $190 | $9 |
| Omeprazole | 32 | $180 | $6 |
| Amlodipine Besylate | 25 | $148 | $6 |
| Metformin | 19 | $123 | $6 |
| Lamotrigine | 12 | $123 | $10 |
| Alendronate | 11 | $120 | $11 |
| Fluoxetine | 12 | $120 | $10 |
| Atenolol | 14 | $98 | $7 |
| Simvastatin | 13 | $92 | $7 |
| Irbesartan-Hydrochlorothiazide | 11 | $75 | $7 |
| Sumatriptan | 13 | $70 | $5 |
| Doxazosin Mesylate | 12 | $55 | $5 |
| Sertraline | 14 | $50 | $4 |
2019: 12 drugs
| Levothyroxine | 24 | $571 | $24 |
| Gabapentin | 20 | $444 | $22 |
| Atorvastatin | 26 | $357 | $14 |
| Losartan | 23 | $206 | $9 |
| Omeprazole | 22 | $167 | $8 |
| Atenolol | 14 | $143 | $10 |
| Fluoxetine | 13 | $125 | $10 |
| Lamotrigine | 13 | $123 | $9 |
| Metformin | 17 | $114 | $7 |
| Metformin Hcl Er | 14 | $114 | $8 |
| Amlodipine Besylate | 13 | $84 | $6 |
| Lisinopril | 12 | $80 | $7 |
2018: 27 drugs
| Advair Diskus | 19 | $7,169 | $377 |
| Movantik | 15 | $6,301 | $420 |
| Humulin 70/30 Kwikpen | 13 | $3,394 | $261 |
| Levothyroxine | 36 | $930 | $26 |
| Atorvastatin | 49 | $750 | $15 |
| Diclofenac | 11 | $558 | $51 |
| Tamsulosin | 16 | $489 | $31 |
| Chlorthalidone | 12 | $455 | $38 |
| Gabapentin | 17 | $385 | $23 |
| Rosuvastatin | 14 | $376 | $27 |
| Losartan | 26 | $312 | $12 |
| Omeprazole | 30 | $298 | $10 |
| Atenolol | 16 | $259 | $16 |
| Escitalopram | 23 | $240 | $10 |
| Metformin | 24 | $202 | $8 |
| Trazodone | 13 | $174 | $13 |
| Alendronate | 13 | $157 | $12 |
| Lisinopril | 22 | $153 | $7 |
| Fluoxetine | 14 | $133 | $9 |
| Paroxetine | 11 | $132 | $12 |
| Glipizide | 18 | $129 | $7 |
| Metformin Hcl Er | 15 | $128 | $9 |
| Triamcinolone Acetonide | 11 | $120 | $11 |
| Amlodipine Besylate | 12 | $112 | $9 |
| Sertraline | 14 | $82 | $6 |
| Simvastatin | 14 | $70 | $5 |
| Hydrochlorothiazide | 13 | $52 | $4 |
2017: 25 drugs
| Humulin 70/30 Kwikpen | 18 | $11,162 | $620 |
| Movantik | 15 | $7,044 | $470 |
| Metformin Hcl Er | 19 | $6,391 | $336 |
| Levothyroxine | 36 | $829 | $23 |
| Tamsulosin | 21 | $826 | $39 |
| Atorvastatin | 70 | $749 | $11 |
| Trazodone | 19 | $469 | $25 |
| Gabapentin | 20 | $452 | $23 |
| Benazepril-Hydrochlorothiazide | 12 | $399 | $33 |
| Metformin | 34 | $332 | $10 |
| Duloxetine | 18 | $330 | $18 |
| Rosuvastatin | 11 | $238 | $22 |
| Sertraline | 15 | $197 | $13 |
| Losartan | 19 | $192 | $10 |
| Triamcinolone Acetonide | 11 | $185 | $17 |
| Lisinopril | 34 | $175 | $5 |
| Amlodipine Besylate | 19 | $161 | $8 |
| Losartan-Hydrochlorothiazide | 13 | $151 | $12 |
| Glipizide | 22 | $146 | $7 |
| Mirtazapine | 13 | $142 | $11 |
| Alendronate | 15 | $139 | $9 |
| Clopidogrel | 13 | $124 | $10 |
| Omeprazole | 21 | $115 | $5 |
| Polyethylene Glycol 3350 | 11 | $110 | $10 |
| Simvastatin | 13 | $62 | $5 |
2016: 9 drugs
| Metformin Hcl Er | 14 | $5,255 | $375 |
| Metoprolol | 11 | $594 | $54 |
| Levothyroxine | 21 | $577 | $27 |
| Atorvastatin | 28 | $373 | $13 |
| Losartan | 14 | $208 | $15 |
| Metformin | 21 | $151 | $7 |
| Amlodipine Besylate | 18 | $103 | $6 |
| Lisinopril | 21 | $84 | $4 |
| Simvastatin | 16 | $71 | $4 |
2015: 6 drugs
| Proair Hfa | 11 | $772 | $70 |
| Pravastatin | 14 | $262 | $19 |
| Omeprazole | 18 | $261 | $14 |
| Levothyroxine | 13 | $200 | $15 |
| Simvastatin | 18 | $112 | $6 |
| Amlodipine Besylate | 12 | $111 | $9 |
2014: 3 drugs
| Hydrocodone-Acetaminophen | 11 | $215 | $20 |
| Omeprazole | 12 | $113 | $9 |
| Simvastatin | 13 | $103 | $8 |
Professional record
- NPI
- 1427312289
- Licence
- CA A130448California A130448: Current · expires 2028-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-06-26
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 960 N San Antonio Rd, Los Altos, CA, 94022